A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer
Phase of Trial: Phase I
Latest Information Update: 23 May 2017
At a glance
- Drugs Panobinostat (Primary)
- Indications Head and neck cancer; Oesophageal cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors Novartis
- 25 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jan 2011 Actual end date (January 2010) added as reported by ClinicalTrials.gov.
- 14 Oct 2008 Status changed from not yet recruiting to recruiting.